Vadlamudi Group - Clinical trials

This project will establish if genomic variants, identified from next generation sequencing, can cause disease. The project then leverages cutting-edge technology to develop a novel drug testing platform, for delivery of optimised and personalised treatment to epilepsy patients. This project is in collaboration with Prof Ernst Wolvetang from The University of Queensland Australian Institute for Bioengineering and Nanotechnology.

This singleton project utilises brain, buccal and blood derived samples from temporal lobe epilepsy patients to look at genes and genetic pathways where the epigenetic state links with epilepsy. By comparing different samples, we will be able to address the issue of tissue specificity in epigenomic studies. This project is in collaboration with A/Prof Jeff Craig, Centre for Molecular and Medical Research, School of Medicine, Faculty of Health Deakin University.

This project provides a novel approach to deepen our understanding of phenotypic expression of idiopathic epilepsies by studying discordant monozygotic twins. The aim of this project is to focus on generating peripheral biomarkers for idiopathic epilepsies to aid in the diagnosis of idiopathic epilepsies and also act as specific markers for idiopathic epilepsy subtypes. The long-term hope of a peripheral biomarker will be the development of disease-modifying treatments. This project is in collaboration with /Prof Jeff Craig, Centre for Molecular and Medical Research, School of Medicine, Faculty of Health Deakin University.

This project builds the resource of an epilepsy twin cohort in Queensland and investigates the role of non-traditional inheritance patterns through monozygotic twin pairs discordant for epilepsy.